Market Closed - Xetra 11:36:33 2024-03-04 am EST After market 03:59:56 pm
65.22 EUR -0.43% Intraday chart for MorphoSys AG 65.37 +0.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
INDEX-MONITOR: Morphosys and Vitesco likely to swap places in March DP
MORPHOSYS : UBS sticks Neutral ZD
Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says MT
INDEX-MONITOR: Morphosys and Vitesco to swap places in MDax and SDax in March DP
MORPHOSYS : UBS revises his opinion and turns to Neutral ZD
European Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday Trading MT
MORPHOSYS : UBS remains its Buy rating ZD
Swiss Market Index Blinks Red Amid Renewed Rate Jitters MT
Global markets live: BP, Palantir, Infineon, Toyota, UBS... Our Logo
Novartis wants to swallow Morphosys - access to beacon of hope DP
Dpa-AFX Overview: COMPANIES from 06.02.2024 - 15:15 DP
Transcript : MorphoSys AG, Novartis AG - M&A Call
North American Morning Briefing : Rate Doubts Keep Pressure on Stocks; More Earnings in Focus DJ
MORPHOSYS : UBS reiterates its Buy rating ZD
European Midday Briefing : Stocks Higher But Gains Capped On Rate Doubts DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
MorphoSys Shares Jump After It Agrees to $2.9 Billion Takeover by Novartis DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
BP earnings, China stimulus lift European stocks at open RE
Morphosys share price approaches Novartis offer DP
Novartis: agreement on a friendly takeover bid for MorphoSys CF
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET DJ
EMEA Morning Briefing : Stock Futures Track Higher as Investors Parse More Fedspeak DJ
Novartis Strikes EUR2.7 Billion Deal to Buy German Biopharmaceutical Group MorphoSys MT
News Highlights : Top Company News of the Day - Monday at 11 PM ET DJ
Chart MorphoSys AG
More charts
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
65.22 EUR
Average target price
50.38 EUR
Spread / Average Target
-22.76%
Consensus
  1. Stock
  2. Equities
  3. Stock MorphoSys AG - Xetra
  4. News MorphoSys AG
  5. European Equities Traded in the US as American Depositary Receipts Ease to Start Week
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW